VERA240517P55000
- 9.50
- 0.000.00%
Vera Therapeutics Newsroom
Vera Therapeutics(VERA.US) Officer Sells US$1.3 Million in Common Stock
$Vera Therapeutics(VERA.US)$ Officer Young Joseph R sold 30,837 shares of common stock on May 15, 16, 2024 at an average price of $42.301 for a total value of $1.3 million.Source: Announcement What is
Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing
Joseph R Young, Senior Vice President, Finance, Chief Accounting Officer, on May 15, 2024, sold 30,837 shares in Vera Therapeutics (VERA) for $1,304,435. Following the Form 4 filing with the SEC, Youn
Institutional Investors in Vera Therapeutics, Inc. (NASDAQ:VERA) Lost 9.3% Last Week but Have Reaped the Benefits of Longer-term Growth
Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their trading actions A total of 9 investors have a majority stake in the company with
Vera Therapeutics | 10-Q: Quarterly report
Vera Therapeutics Is Maintained at Strong Buy by Raymond James
Vera Therapeutics Is Maintained at Strong Buy by Raymond James
Vera Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 66.34% Raymond James $57 → $68 Maintains Strong Buy 04/05/2024 36.99% Guggenheim → $56 Reiterat
Express News | Vera Therapeutics Inc : Raymond James Raises Target Price to $68 From $57
Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating
Vera Therapeutics (VERA) has an average rating of buy and price targets ranging from $25 to $107, according to analysts polled by Capital IQ. Price: 41.55, Change: -0.78, Percent Change: -1.84
Express News | UPDATE: Vera Therapeutics Q1 EPS $(0.56) Up From $(0.80) YoY
Vera Therapeutics 1Q Loss/Shr 56c >VERA
Vera Therapeutics 1Q Loss/Shr 56c >VERA
Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results -- Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard
Express News | Vera Therapeutics Q1 Operating Income USD -31.112 Million Vs. Ibes Estimate USD -27.9 Million
Express News | Vera Therapeutics Q1 EPS USD -0.56 Vs. Ibes Estimate USD -0.53
Express News | Vera Therapeutics Q1 Operating Expenses USD 31.112 Million
Express News | Vera Therapeutics Inc: Qtrly Net Loss per Diluted Share of $0.56
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducem
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a res
Could This Stock Be the Next Biotech Buyout?
Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...
Vera Therapeutics(VERA.US) Officer Sells US$228.56K in Common Stock
$Vera Therapeutics(VERA.US)$ Officer Young Joseph R sold 5,714 shares of common stock on Apr 10, 2024 at an average price of $40 for a total value of $228.56K.Source: Announcement What is statement of